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Abstract
Missense mutant proteins, such as those produced in individuals with genetic diseases, are often misfolded and subject to
processing by intracellular quality control systems. Previously, we have shown using a yeast system that enzymatic function
could be restored to I278T cystathionine b-synthase (CBS), a cause of homocystinuria, by treatments that affect the
intracellular chaperone environment. Here, we extend these studies and show that it is possible to restore significant levels
of enzyme activity to 17 of 18 (94%) disease causing missense mutations in human cystathionine b-synthase (CBS)
expressed in Saccharomyces cerevisiae by exposure to ethanol, proteasome inhibitors, or deletion of the Hsp26 small heat
shock protein. All three of these treatments induce Hsp70, which is necessary but not sufficient for rescue. In addition to
CBS, these same treatments can rescue disease-causing mutations in human p53 and the methylene tetrahydrofolate
reductase gene. These findings do not appear restricted to S. cerevisiae, as proteasome inhibitors can restore significant CBS
enzymatic activity to CBS alleles expressed in fibroblasts derived from homocystinuric patients and in a mouse model for
homocystinuria that expresses human I278T CBS. These findings suggest that proteasome inhibitors and other Hsp70
inducing agents may be useful in the treatment of a variety of genetic diseases caused by missense mutations.
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Introduction
Missense mutations are genetic alterations that result in the
production of proteins with single amino acid changes and are an
especially common cause of a variety of diseases [1]. Most disease
causing missense mutations do not target key catalytic residues,
but rather cause problems in protein folding. It is thought that
missense mutations affect protein folding by ‘‘trapping’’ the
protein in a non-functional intermediate state, preventing it from
folding into its lowest-free energy native state. These trapped
misfolded protein intermediates can either be degraded or form
large molecular weight aggregates [2]. In theory, treatments that
could reverse these protein-folding defects and promote proper
folding would be of great utility in the treatment of a wide variety
of genetic diseases.
Three genetic diseases in which missense mutations are
common include cystathionine b-synthase (CBS) deficiency, Li
Fraumeni syndrome, and methylenetetrahydrofolate reductase
deficiency. CBS deficiency is an inborn error of sulfur metabolism
characterized by very high levels of plasma total homocysteine
(tHcy). CBS catalyzes the condensation of homocysteine with
serine to form cystathionine and is the first step in the de novo
production of cysteine. In healthy adults, tHcy concentration in
plasma ranges from 5 to 15 mM, but untreated patients with CBS
deficiency often have tHcy in excess of 200 mM [3]. CBS deficient
patients suffer from various pathologies including arteriosclerosis,
osteoporosis, mental retardation, and dislocated lenses [4]. The
major cause of mortality in these patients is stroke. Treatments
that lower tHcy such as B-vitamins, dietary methionine restriction,
and betaine supplementation, can significantly reduce the inci-
dences of vascular events in these patients despite the fact that
post-treatment homocysteine levels are still several times higher
than levels found in the normal population [5,6,7]. Mouse models
for CBS deficiency also indicate that there is a threshold effect for
tHcy toxicity and support the notion that a small increase in
residual CBS activity may have large clinical benefits [8].
Li-Fraumeni syndrome is a dominant cancer susceptibility
syndrome disorder caused by missense mutations in the TP53
tumor suppressor gene [9]. Li-Fraumeni patients suffer from a
variety of cancers, including sarcomas, adrenocorticol carcinomas,
breast cancer, leukemia, and brain tumors [10]. In general, TP53
behaves as a classic tumor suppressor gene, with the tumors losing
or inactivating the wild-type copy of TP53, resulting in expression
of only the mutant form. Mutant forms of p53 tend to be stable,
resulting in increased accumulation of protein [11]. Of the 165
mutations in the TP53 gene described in the Human Gene
Mutation Database [12], 110 are of the missense variety (68%).
MTHFR is a critical enzyme in the remethylation of homocys-
teine to methionine. Its biochemical function is to catalyze the
formation of 5-methyltetrahydrofolate, which is the methyl-group
donor for the subsequent reaction catalyzed by methionine
synthase. Mutations in MTHFR are known to cause MTHFR
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delay, motor or gait abnormalities, seizures, and premature vascular
disease [13]. Thirty-four mutations have been described in
MTHFR deficient patients, and 23 are predicted to encode
missense mutations (67%) [12].
Previously, work from our lab has shown that it is possible to
restore significant enzymatic function to human CBS containing
an isoleucine to threonine substitution at position 278 (I278T) by
growth of cells in ethanol containing media [14]. This rescue was
shown to require the induction of Hsp70, a key cellular chaperone
protein [15]. Hsp70 protein interacts with misfolded polypeptides
along with co-chaperones and promotes refolding by repeated
cycles of binding and release requiring the hydrolysis of ATP [16].
In the work described here, we have extended our observations by
showing that treatments that induce Hsp70 can greatly increase
enzymatic function from 17 additional mutant CBS proteins, as
well as mutant forms of p53 and MTHFR. In addition we show
that proteasome inhibitors can induce Hsp70 and that these drugs
can greatly increase mutant CBS activity in human cells and in a
mouse model of CBS deficiency. Our findings support the idea
that drugs that induce Hsp70 may be useful in the treatment of
genetic disorders caused by missense mutations.
Results
Ethanol and deletion of HSP26 restores enzymatic activity
to mutant human CBS
We initially examined the effect of ethanol on a panel of 17
additional missense CBS mutations found in homocystinuric
patients [17]. Each of these mutations was expressed in a yeast
strain (WY35) that is deleted for the endogenous CBS gene (cys4D)
and growth was examined on cysteine-free media either lacking or
containing 4% ethanol (Figure 1A). In addition, we prepared total
cellular lysates from the strains grown in cysteine-supplemented
media with or without ethanol and measured both the steady state
level of each mutant protein by Western blot and CBS enzyme
activity (Figure 1B and 1C, Figure S1, Table 1). We found that
4/17 (24%) of the mutants exhibited significant growth and greatly
increased CBS enzyme activity (8 to 50-fold) when grown in
ethanol-containing media. Interestingly, like I278T, ethanol had a
much more modest effect on steady state protein levels compared
to enzyme activity, indicating that the treatment caused the
specific activity of the enzyme to increase. Ethanol exposure also
increased steady state Hsp70 levels, consistent with our previous
observations (Figure 1B).
Previously, we had also shown that deletion of the small heat
shock protein HSP26 (hsp26D) could effectively suppress the
functional effects of I278T CBS mutation in yeast [14]. Therefore,
we introduced our panel of additional missense mutants into a
cys4D hsp26D double mutant strain and examined function. As
with ethanol, hsp26D resulted in increased steady state levels of
Hsp70 (Figure 1E). Deletion of Hsp26 could rescue the cysteine
growth auxotrophy and restore significant levels of enzymatic
activity to 10/17 (59%) of the mutants tested (Figure 1D–1F,
Figure S2, Table 1). Again, the increased level of enzyme activity
in the suppressible mutants was impressive, ranging from an 8 to
55-fold increase resulting in levels that were between 25% and
58% of wild-type CBS. Like ethanol, most of the increased enzyme
activity appears to be due to increased functionality of the mutant
protein as opposed in increased protein levels.
In our earlier work, we had shown that expression of I278T
CBS drove down levels of Hsp26 protein and that I278T CBS, but
not wild-type CBS, physically interacted with Hsp26 [14]. We
tested two of the newer mutants (G307S, D376N) for these
properties and found that they also caused decreased steady state
levels of Hsp26 and co-immunoprecipitated Hsp26 (Figure S3).
These results indicate that like I278T, G307S and D376N form a
complex with Hsp26.
Bortezomib rescues several forms of mutant human CBS
expressed in S. cerevisiae
Since proteasome inhibitors have previously been shown to
induce Hsp70 in both yeast and mammalian cells [18,19], we tested
if these agents might be able to restore function to missense mutant
CBS proteins in vivo. Bortezomib (also known as PS-341 or Velcade)
is a potent proteasome inhibitor that is currently used to treat
humans with multiple myeloma [20]. We first tested the effects of
bortezomib on mutant human I278T CBS function in yeast. We
found that addition of bortezomib to yeast media strongly rescued,
in a dose-dependent fashion, the cysteine auxotrophy of WY35 cells
carrying a plasmid expressing human I278T CBS (pI278T)
(Figure 2A). After 24 hours, 75 mM bortezomib allowed WY35-
pI278T cells to achieve growth that was at least equivalent to WY35
expressing wild type human CBS (phCBS). Examination of I278T
protein and activity from treated vs. untreated cells indicated that
bortezomib increased steady-state levels of I278T by 7-fold and
increased I278T activity by 27-fold, to about 50% of that observed
in untreated cells expressing wild-type CBS (Figure 2B). These
results show that bortezomib can both stabilize and restore function
to I278T CBS expressed in yeast.
Bortezomib treatment also caused a 2.8 to 3.6-fold increase in
Hsp70 in WT and I278T expressing strains, respectively
(Figure 2B). To determine if this induction was essential for
restoration of I278T CBS function, we examined the effect of
bortezomib on yeast lacking the Hsp70-encoding gene SSA2
(ssa2D; Figure 2C). As expected, steady state levels and the enzyme
activity of I278T CBS were lower compared to wt CBS in both
SSA2 and ssa2D cells in the absence of bortezomib. In the presence
of bortezomib, we saw stabilization of I278T protein in ssa2D cells,
but no increase in enzyme activity. In ssa2D cells expressing WT
CBS, we did not observe any decrease in enzyme activity,
indicating that SSA2 is not required generally for human CBS
function. These results show that simply blocking proteolysis of
Author Summary
Genetic diseases are often caused by missense mutations:
single nucleotide changes that cause a single incorrect
amino acid to be substituted into the underlying protein.
Most missense mutations cause the encoded protein to
fold incorrectly and therefore not function properly.
Examples of missense mutation diseases include CBS
deficiency, Li-Fraumeni syndrome, and methylenetetrahy-
drofolate reductase deficiency, which are caused by
alterations in the CBS, TP53, and MTHFR genes, respective-
ly. In the work presented here, we show that it is possible
to restore substantial enzymatic function to disease-
causing human mutant CBS, p53, and MTHFR proteins by
treatments that alter the intracellular folding environment.
All of these treatments result in elevation of the Hsp70
protein, a molecular chaperone protein involved in helping
proteins fold properly. One way to rescue mutant protein
function is by using a drug that inhibits the function of the
proteasome, the intracellular machine responsible for
degrading misfolded proteins. Our findings suggest that
drugs of this class may be potentially useful in the
treatment of human genetic diseases caused by missense
mutations.
Rescue of Mutant CBS by Induction of Hsp70
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enzyme, and that SSA2 (Hsp70 protein) is required for bortezomib-
induced rescue of function.
We also investigated the effect of bortezomib on our panel of
other patient-derived CBS mutants. We found that 9/17 of the
alleles tested showed significant growth in cysteine-free media and
had enzyme activity restored to between 37–68% of wild-type
CBS (Figure 2D). It should be noted that some of these mutants
(T353M and T262M for example) produce stable but non-
functional enzymes, indicating that bortezomib is not simply
working by preventing protein degradation (Figure S4)
Restoration of function to mutant forms of p53 and
MTHFR
We next determined if chaperone manipulation could be used
to restore function to disease causing mutants of p53 and
MTHFR. To examine p53 function, we used a yeast strain
(yIG397) in which human p53 binds upstream of the ADE2
promoter, activates transcription, and results in correction of the
strains adenine auxotrophy [21]. Into this strain we transfected
plasmids that expressed either wild-type human p53 or one of
three different patient-identified point mutations (R175H, R273H,
C277F) and measured p53 function by examining growth in
Figure 1. Functional rescue of mutant CBS by ethanol and hsp26D. (A) A stationary phase culture of yeast (WY35) transformed with a plasmid
expressing the indicated human CBS allele was diluted 1:1000 in SC–Cys media with or without 4% ethanol and grown at 30uC for 24 h. Growth was
determined by measuring OD at 600 nm. (B). Western analysis of two representative ethanol rescuable (T353M, T262M) and two non-rescuable
(G307S, D376N) mutants. Cells were grown in SC+CYS media with or without ethanol and extracts were probed with indicated antibody. (C) CBS
enzyme activity of each of the mutant alleles in the presence and absence of ethanol. (D) Growth of HSP26 (WY35) or hsp26D (LS2) yeast expressing
the indicated CBS allele. (E) Western analysis of two representative hsp26D rescuable (T353M, A231L) and two non-rescuable (T191M, L101P) mutants.
(F) CBS enzyme activity of each of the mutant alleles in the presence and absence of Hsp26.
doi:10.1371/journal.pgen.1000807.g001
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expressing wild type human p53 grew well, while cells expressing
the mutant alleles had almost undetectable levels of growth
(Figure 3A). However, when the media was supplemented with
either 4% ethanol, 50 mM Bortezomib, or an hsp26D construct was
introduced into the strain, each mutant exhibited significant
growth rescue with at least one of the treatments.
We performed more in depth analysis on two of the mutant
alleles, R175H and R273H. In the absence of ethanol, steady state
levels of both of these mutant proteins are slightly elevated
compared to wild type CBS and cause elevations in the steady
state levels of Hsp26 and Hsp104 (Figure 3B). The elevation in
Hsp104 was unexpected, as we had previously shown that I278T
CBS had no effect on Hsp104 levels [14]. When ethanol is added
to the cultures, Hsp70 levels are induced and p53 and Hsp26 levels
are reduced to wild-type levels, while hsp104 levels remain
elevated. The observation that p53 levels go down, while growth
increases indicates that, like CBS, ethanol is enhancing the specific
activity of p53.
We also examined the dependence of ethanol rescue on having
a functionally intact SSA2 and HSP104 (Figure S5). Deletion of
either gene resulted in total loss of the ability of ethanol to promote
adenine independent growth. Immunoprecipitation experiments
demonstrate that, similar to mutant CBS, Hsp26 recognizes
mutant p53 but not wild-type p53 and that this interaction is lost
upon ethanol treatment. (Figure 3C). Taken together, these results
show that p53 mutants behave similar, but not identical, to CBS
mutants with regards to rescue by agents that perturb the cellular
chaperone environment.
We next determined the frequency by which defective p53
protein could be rescued by either ethanol or bortezomib
treatment. We examined rescue using a panel of 22 single
missense mutant p53 alleles that were obtained by random
mutagenesis of the human p53 (see Materials and Methods). Like
CBS, we found that some mutants were rescuable by both ethanol
and bortezomib (4/22), some only by bortezomib (8/22), some
only by ethanol (4/22), and some that were not rescuable by either
treatment (6/22). In total, we found that 16 out of 22 (72%) of the
randomly generated mutants were rescuable by at least one of the
treatments (Figure S6).
We have also examined the effect of ethanol and bortezomib on
mutant alleles of human 5–10-methylene tetrahydrofolate reduc-
tase (MTHFR) expressed in yeast. In this assay, expression of a
functional human MTHFR enzyme complements the methionine
auxotrophy present in a met11D mutant [22]. Two missense
mutant MTHFR proteins were tested for growth rescue by either
addition of ethanol or bortezomib and we found that one, L323P,
could be rescued by the addition of ethanol (Figure 3D).
Restoration of CBS function in patient fibroblasts by
MG132
We next determined if the restoration of function we observed
in S. cerevisiae could also occur in mammalian cells. To test this, we
examined the effect of proteasome inhibitors on mammalian cells
expressing mutant human CBS protein. We obtained four primary
fibroblast lines and one EBV transformed lymphoblastoid line
from five patients with CBS deficiency. Four of the five lines were
from patients that were homozygous for a particular mutation
(I278T, T353M, T262M, G307S), while one line was from a
compound heterozygote (A114V/E302K). We then examined
both steady state CBS protein and CBS enzyme activity in
untreated and in cells treated with the proteasome inhibitor
MG132 (Figure 4A). MG132 was used in these experiments
because it was found to be a more potent inducer of Hsp70 than
Table 1. Relative levels are shown for CBS protein and activity in yeast.
Protein Levels Activity Levels
Mutants No treatment Ethanol Bortezomib DHsp26 No treatment Ethanol Bortezomib DHsp26
WT 1.0 2.2 1.6 1.2 100 149 120 96
G307S 0.9 0.4 2.4 1.1 1 3 2 57
T262M 1.1 1.2 2.2 1.2 3 44 68 3
D376N 1.4 0.6 2.2 1.4 1 3 2 50
T353M 0.7 1.1 2.3 1.6 3 25 44 37
A231L 0.3 1.4 2.1 1.2 1 45 3 35
T191M 0.7 0.3 6.1 1.7 1 4 2 48
G151R 0.7 0.2 1.6 0.8 1 4 35 1
L101P 0 0 1.2 0.9 1 4 28 1
N228S 1.4 0.7 2.1 1.6 2 4 29 40
Q528K 1.5 0.7 2.8 2.3 1 3 17 1
L496P 0 0 1.9 0.9 1 3 2 66
G116R 0 0 1.2 0 1 3 3 1
A114V 0 0 ND ND 14 15 70 13
V320A 1.5 0.8 1.8 1.8 2 2 84 54
R224H 0.3 0.3 2.2 1.2 1 55 28 1
V168M 0.3 0.3 1.9 1.0 1 4 2 67
A226T 1.0 ND 1.6 1.6 2 2 22 68
I278T 0.2 0.6 1.4 0.6 2 65 49 59
Protein is normalized to 1 while enzyme activity is normalized to 100 for wild-type human CBS.
doi:10.1371/journal.pgen.1000807.t001
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PLoS Genetics | www.plosgenetics.org 4 January 2010 | Volume 6 | Issue 1 | e1000807Figure 2. Functional rescue of mutant human CBS expressed in S. cerevisiae by bortezomib treatment. (A) A stationary phase culture of
yeast (WY35) transformed with a plasmid expressing either WT (phCBS) or I278T (pI278T) human CBS was diluted 1:1000 in SC–Cys media with the
indicated amount of bortezomib and grown at 30uC for 24 h. Growth was determined by measuring OD at 600 nm. (B) WY35 pI278T and WY35
phCBS cells were grown in SC–Trp+Cys media either with or without 50 mM of bortezomib for 24 hours and extracts were prepared. Levels of CBS, a-
tubulin, and Hsp70 and CBS activity were assessed as described in Materials and Methods. CBS units are nmole cystathionine formed/mg protein-hr.
(C) Yeast strain WY35 phCBS, WY35 pI278T, LS3 phCBS, LS3 pI278T were grown at 30uC in the absence and presence of bortezomib and extracts were
assessed for CBS activity and CBS protein. (D) Stationary phase cultures of yeast strain WY35 expressing the indicated allele of CBS were diluted
1:1000 in SC–Cys media either with or without 50 mM of bortezomib and growth was monitored by OD600 after 24 h at 30uC. (E) Log phase cultures of
WY35 grown in SC+Cys media with or without 50 mM of bortezomib expressing the indicated CBS allele were harvested, lystates prepared, and CBS
enzyme activity was measured and expressed in units.
doi:10.1371/journal.pgen.1000807.g002
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of the five lines (I278T, T253M, and A114V/E302K) had
undetectable levels of CBS protein and all five lines had ,1%
enzyme activity compared to a control primary human fibroblast
line. Addition of MG132 resulted in restoration of steady-state CBS
to wild-type levels in all five lines and caused a dramatic increase in
enzyme activity (over 100-fold increase to 28 to 66% of wt CBS) in
three of the five lines (I278T, T353M, and T262M). Interestingly,
the increase in enzyme activity in the T262M cells was not
associated with increased T262M protein levels, again suggesting
that the rescuing effect of proteasome inhibitors is not due to
inhibition of mutant protein degradation. Consistent with this idea,
we found that MG132 resulted in a two-fold increase in Hsp70
(Figure 4A). With one exception, we note concordance in the
behaviorofmutants thatwererescuable byproteasome inhibitionin
yeast and in patient fibroblasts. It is possible that the lack of rescue
observed in the A114V allele may have to do with the cell line also
having the E320K allele as well. In total, these results indicate that
exposure of human cells to proteasome inhibitors can rescue
enzymatic activity from several missense mutant CBS proteins.
Increased CBS activity and lower plasma homocysteine in
Tg-I278T Cbs
2/2 mouse treated with bortezomib
Previously we had developed a mouse model for homocystinuria
caused by I278T CBS (Tg-I278T Cbs
2/2). This mouse contains a
homozygous deletion of the mouse CBS gene, and expresses
human I278T CBS under control of a zinc-inducible promoter
[23]. In this animal it was demonstrated that human I278T CBS
expressed in mouse liver had minimal enzyme activity [24]. To test
the effect of bortezomib in vivo, we induced I278T expression by
addition of zinc to the drinking water, and after one week injected
30 mg of bortezomib into the tail veins of four Tg-I278T Cbs
2/2
animals. After 17 hours, serum, liver and kidney were then
harvested and analyzed. Examination of steady state CBS protein
indicates that bortezomib greatly increased the amount of liver
I278T protein and Hsp70 protein compared to a mock-injected
control (Figure 4B). In addition, CBS enzyme activity increased on
average 4.3-fold in the livers of treated animals compared to
untreated controls, to about 18.7% of that found in an animal that
expresses wild-type human CBS (Figure 4B). We also observed
increased enzyme activity in kidney extracts in two of the four
injected animals (Figure 4B). Interestingly, the kidney does not
show significantly increased steady-state I278T protein, indicating
that the increased enzyme activity is due entirely to increased
enzyme specific activity. Bortezomib treatment resulted in a 46%
decrease in tHcy in serum, (p,0.05) (Figure S8). Bortezomib also
resulted in a 28% decrease in serum methionine, although this was
not statistically significant (Figure S8). These results indicate that
bortezomib can decrease tHcy in vivo by increasing residual I278T
enzyme activity.
Figure 3. Functional rescue of mutant p53 and MTHFR in yeast. (A) Yeast p53 tester strain yIG397 (HSP26), or LS2 (hsp26D) were transformed
with an expression plasmid expressing the indicated p53 alleles. Stationary phase cultures of yeast expressing the wild type and indicated mutant
were diluted 1:1000 in SC-ura -ade media grown in 15 ml tubes with aeration at 30uC for 24 hours. Where indicated, 4% ethanol or 50 mM bortezomib
were added to the media. (B) Yeast strain yIG397 carrying the indicated p53 alleles was grown in adenine containing media with or without 4%
ethanol. Lysates were then probed by Western Blot with the indicated anti-bodies. (C) Yeast strains yIG397 and LS2 expressing the indicated p53
alleles were grown in adenine containing media supplemented with 4% ethanol when indicated. Lysates were prepared and immunoprecipitation
was performed with anti-p53 antibody and Hsp26 present in the immune complexes was analyzed by immunoblot. (D) Yeast MTHFR tester strain
XSY3-1A (met11D) were transformed with expression plasmids expressing the indicated MTHFR allele.
doi:10.1371/journal.pgen.1000807.g003
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In the work described here, we have shown that it is possible to
restore substantial amount of functional activity to a large
percentage of missense mutant alleles of human CBS, p53, and
MTHFR expressed in S. cerevisiae by treatments that cause Hsp70
induction. These treatments include addition of ethanol or
proteosome inhibitor to the media, or deletion of the small heat
shock protein HSP26. At least one of these treatments was able to
dramatically increase enzyme or transcriptional activity in 17/18
(94%) mutant CBS proteins, 19/25 mutant p53 proteins (76%),
and 1/2 mutant MTHFR proteins (50%). Interestingly, different
types of response to the different rescuing treatments were
observed. Some mutants were rescued by all three treatments
(e.g. I278T CBS), some by two of three treatments (e.g. T262M
CBS), while others only responded to a single treatment (e.g.
G307S CBS). These differences are probably not due to
differential Hsp70 induction, as all three treatments result in
similar levels of induction. We speculate that each of these
different treatments may have unique effects on other molecular
chaperones and that each treatment may produce a unique
intracellular folding milieu. With regards to CBS mutants, we
found that both pyridoxine responsive mutants (e.g. I278T) and
non-responsive mutants (e.g. G307S) could be rescued.
Figure 4. Functional rescue of mutant CBS by proteosome inhibitors in mammalian cells. (A) Restoration of CBS enzyme activity in patient
fibroblasts. Primary fibroblast cells expressing the indicated CBS allele were grown to 80% confluency at which time MG132 (18 mM) was added. After
seven hours protein was harvested and Hsp70, CBS, and actin protein levels were measured by immunoblot. CBS activity was measured and activity is
expressed as nmole cystathionine formed/mg protein-hr. Note that the G307S cell line is a transformed lymphoid cell line. (B) Effect of intravenous
bortezomib treatment on Tg-I278T Cbs
2/2 mice. Tg-I278T Cbs
2/2 mice were kept on zinc water for 10 days to induce transgene expression and then
either injected with bortezomib (30 mg) or saline by tail vein injection. After 17 hours mice were sacrificed and tissues harvested. Immunoblot analysis
of CBS in liver and kidney extracts from bortezomib treated ‘‘B’’ and non-treated (NT) I278T mice. Actin was used as loading control. CBS activity was
measured and activity is expressed as nmole cystathionine formed/mg protein-hr. Mice labeled ‘‘No Tg’’ are Cbs
2/2 animals lacking human CBS. Lane
labeled ‘‘C’’ contains extract from a Tg-I278T Cbs
+/2 animal. Bar graph shows Liver CBS activity in bortezomib treated (n=4) and non-treated (n=4)
Tg-I278T Cbs
2/2mice was compared with CBS activity in a non-treated mouse containing normal hCBS. Statistical significance was calculated by t test.
Results are represented in terms of mean6SE. *P,0.05.
doi:10.1371/journal.pgen.1000807.g004
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primarily affect protein folding, as opposed to altering critical
residues involved in specific catalytic or interaction sites. This
agrees with biophysical studies of protein folding. As stated by
DePristo et al. [25] ‘‘The overwhelming conclusion from 20 years
of mutation studies on protein stability is that most amino-acid
replacements, at all sites in a protein result in large effects on DG
relative to the observed range of DG values themselves.’’ It is also
possible that in multi-domain proteins like CBS, mutations affect
protein folding by trapping the protein in a non functional
intermediate state due to the existence of a high kinetic barrier [2].
Therefore, a possible explanation for the effectiveness of
chaperone manipulation is that chaperone complex either helps
mutant proteins overcome rate-limiting kinetic constraints in the
folding process or brings the trapped intermediate back to a
folding competent state. Interestingly, in CBS, only one mutation,
G116R, was not rescuable by any treatment. This mutation is
located only three residues away from the lysine (K119) that binds
the active site pyridoxal phosphate at the base of an alpha helix
[26]. Thus this change may be an example of a mutation that
affects a key catalytic-site in the protein.
Our results also show that this is not a yeast-specific
phenomenon. We were able to restore function to three of six
mutant alleles present in fibroblast cells from CBS deficient
patients by treatment with the proteasome inhibitor MG-132. In
addition, we showed that a 4.3-fold increase in CBS activity could
be achieved with a single injection of bortezomib into mice
expressing I278T CBS. Consistent with our findings, Mu et al.
showed that MG-132 could increase residual glucocerebrosidase
enzyme activity four-fold in cell lines containing the L444P variant
associated with Gaucher disease, and that a combination of MG-
132 and a chemical chaperone, 2-Acetamido-2-deoxynojirimycin,
could increase residual activity five-fold in cells containing the
Tay-Sachs disease causing a-hexosaminidase G269S mutation
[27]. In addition, the Hsp70-inducing drug arimoclomol was
reported to delay disease progression in mice expressing a SOD1
mutant in which glycine is substituted with alanine at position
93 [28].
Taken together, these findings suggest that treatment with
proteasome inhibitors and other Hsp70 inducers may be beneficial
to individuals with severe genetic diseases caused by missense
mutation. One potential concern with drugs that manipulate the
molecular chaperone environment is they may have potential
adverse effects on the normal proteome, and thus create side
effects that would preclude their use as drugs. While this is a
possibility, it should be noted that Bortezomib is already an FDA
approved drug that is used to treat multiple myeloma. The major
noted toxicity is peripheral neuropathy [29]. However, it is
unknown if the levels of Bortezomib used to induce changes in the
chaperone environment would need to be as high as those used in
chemotherapy. Furthermore, there is another proteasome inhib-
itor in clinical trials (PR-171) that does not exhibit a strong
peripheral neuropathy effect [30]. In addition, there are at least
two other drugs that are known Hsp70 inducers that have
undergone successful phase I trials in humans including 17-
allylamino-17-demethoxygeldanamycin and arimoclomol [31,32].
Therefore, while there may be some risk in this approach, there is
no reason a priori to believe that the benefits of restoring function to
a mutant protein would not out weigh the potential side effects.
In addition to germline genetic diseases, the work described
here may have relevance to the treatment of somatic genetic
diseases such as cancer. Mutations in p53 are the most frequent
genetic alteration in human cancer, and loss of p53 function is
critical for tumorigenesis [33]. Several pharmacologic chaperones
that restore function to mutant p53 protein have been identified
and these have been shown to effectively induce apoptosis in
certain cells that express mutant p53 [34,35]. Our findings suggest
that proteasome inhibitors may also effectively restore function to
certain p53 alleles. Although bortezomib has been shown to inhibit
cell growth and cause apoptosis in a large number of cancer cell
lines, the IC50 concentrations vary widely [36]. No systematic
study of the relationship between bortezomib sensitivity and the
p53 status of tumor cells has been reported.
In summary, the data reported here shows that the functional
effects of a majority of missense mutations in at least three human
genes can be reversed by treatments that alter the intracellular
molecular chaperone environment. Based on these results, we
suggest that drugs that effect the intracellular chaperone
environment may be useful in the treatment of a number of
genetic diseases caused by missense mutations.
Materials and Methods
Yeast strains, plasmids, growth, and drug treatment
Yeast strains WY35 (a leu2 ura3 ade2 trp1 cys4::LEU2), LS1 (a leu2
ura3ade2trp1cys4::LEU2hsp26::KanMX)an dLS 3( aleu2ura3ade2trp1
cys4::LEU2 ssa2::KanMX) were generated as previously described
[14,37]. Yeast strain yIG397 (MATa ade2-1 leu2-3,112 trp1-1 his-
11,15 can1-100, ura3-1 URA3 3XRGC::pCYC1::ADE2) was obtained
from Dr. Richard Iggo [21]. Strains LS3 (yIG397+hsp26D), LS4
(yIG397+ssa2D) and LS5 (yIG397+hsp104D) were derived from this
strain by transformation with appropriate deletion cassettes as
previously described [14]. The MTHFR tester strain, XSY3-1a
(MATa ade2-1, can1-100, ura3 leu2 trp1, his3, trp1 met11D::TRP1)w a s
created as previously described [22]. Plasmids expressing wild-type
or mutant human CBS proteins were created by site-directed
mutagenesis and gap-repair as described [38,39]. The plasmids
expressing mutant p53 alleles were constructed using gap repair with
pRDI-22 [21]. Additional p53 mutants were generated by
amplification with TaqI polymerase, followed by gap-repair and
subsequent screening on SC-ade media for non-functional alleles.
Ninety-six clones were then isolated and sequenced. Twenty-three of
these clones contained a single missense mutation and were used for
the studies described here. Bortezomib (Velcade
TM, Millennium
Pharmaceuticals, Inc) was obtained from the Fox Chase Cancer
Center outpatient clinic. Synthetic complete media lacking cysteine
(SC–Cys) and (SC–Cys+G418) were made as previously described
[14]. SC+Cys media were made by adding glutathione to the
indicated SC media at a final concentration of 30 mg/ml. All other
chemicals were purchased from Sigma. For yeast cell growth assays,
saturated cultures were diluted to an OD600 of 0.05 and treated with
bortezomib in standard 15-ml borosilicate tubes containing 3 ml of
media. Cells were then grown at 30uC with rotating aeration. After
24 hours OD600 was determined using a Milton Roy Spectronic 601
spectrophotometer (Ivyland, PA).
Cell lines and drug treatment
Cell lines used in this study were: WS1 (WT) [40], F5889
(I278T/I278T) [41], 382 (T262M/T262M ) [42], 2242 (A114V/
E302K) [43], 3161 (T353M/T353M, JPK unpublished), 3079
(G307S/G307S) [44]. Fibroblasts and EBV transformed lymphoid
cells were grown in MEM or RPMI medium supplemented with
15% FBS along with appropriate antibiotics, respectively, in 5%
CO2 at 37uC. MG132 was purchased from Peptide International
(product number, IZL-3175v). MG132 or bortezomib was added
to cells when they reached 80% confluency and after seven hours
of exposure, the MG132 containing media was discarded, cells
were rinsed with PBS, and then harvested for protein extraction.
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Saturated yeast were diluted to an OD600 of 0.05 and cells were
harvested when OD was between 0.7 and 0.9 (mid-log phase). Yeast
extracts were prepared by mechanical lysis as described previously
[45]. Total mammalian protein extracts were prepared using the
mammalian protein extraction reagent obtained from Pierce,
Rockford, IL (product # 78501). Protein concentration was
determined by the Coomassie Blue protein assay reagent (Pierce)
using bovine serum albuminasa standard. For immunoblot analysis,
yeast extracts containing 20 mg or mammalian cell containing 50 mg
of total protein were run on precast Tris-acetate gels (Bio-Rad) at
15 mA and transferred to polyvinylidene difluoride membrane as
previously described [14]. Immunopurified mouse anti-CBS was
purchased from ABNOVA (catalogue # H00000875-A01) and was
used at 1/10,000 dilution. Anti-p53 is a mouse monoclonal anti-
body obtained by Calbiochem (cat. #OP43) and was used at a 1/
1000 dilution. Yeast Hsp70 monoclonal mouse serum was from
AbCAM (catalogue # ab5439) and used at a dilution of 1/5000.
Human Hsp70 monoclonal antibody (product # SPA-810D) was
used at 1/1000 dilution. A-Tubulin antibody used here is the same
as described previously [14]. For rabbit antiserum, a horseradish
peroxidase-conjugated anti-rabbitsecondary anti-bodywas used at a
1/30,000 dilution (Jackson ImmunoResearch, West Grove, PA).
Signal was detected by chemiluminescence using SuperSignal West
Pico chemiluminescent substrate (Amersham Biosciences) and
Chemigenius station (Syngene); signal was quantitated by Alpha
Innotech software. Immunopreciptiations were performed as
previously described [14].
Mouse studies
All animal studies were reviewed and approved by the Fox Chase
Cancer Center Institutional Animal Care and Use Committee. Tg-
hCBS Cbs
2/2 and Tg-I278T Cbs
2/2 mice were generated as
previously described [23,46]. All mice were from C57BL6 strain
background and were fed the rodent chow (Teklad2018SX; Harlan
Teklad, Madison, WI, USA) ad libitum. Adult mice (9–12 months
old) were injected with 30 ml of bortezomib (1 mg/ml) via tail vein
injection. After 17 hour, mice were sacrificed and liver, kidney and
serum were extracted. Liver and kidney homogenates were
prepared as previously described [46]. Western blotting was done
under denaturing conditions as previously described [47].
CBS activity and metabolite measurement
CBS activity was measured in 30 mg of crude dialyzed protein
extracts of liver and kidney, using a Biochrom 30 amino acid
analyzer (Biochrom, Cambridge, UK) as described previously [47].
One unit of activity is one mM of cystathionine formed per hour per
milligramofprotein.Thesameinstrumentwasemployedtomeasure
total homocysteine (tHcy) and methionine in serum as described [8].
Supporting Information
Figure S1 CBS protein levels in all mutants grown in the
presence or absence of ethanol. Cys4D cells (Wy35) were grown in
SC+CYS media either in the absence or presence of 4% ethanol.
After strains reached an OD600,1.5, extracts were prepared and
Western analysis was performed using CBS antibody.
Found at: doi:10.1371/journal.pgen.1000807.s001 (0.28 MB PDF)
Figure S2 CBS protein levels in all mutants grown in the
presence or absence of Hsp26. The indicated mutants were
expressed in either a cys4D strain (Wy35) or a cys4Dhsp26D strain
were grown in SC+CYS media, extracts were prepared, and
Western analysis was performed using CBS antibody.
Found at: doi:10.1371/journal.pgen.1000807.s002 (0.40 MB PDF)
Figure S3 Interaction of D376N and G307S CBS with Hsp26.
(A) The indicated mutants were expressed in either a cys4D strain
(Wy35) or a cys4Dhsp26D (LS1) strain. Cells were grown in
SC+CYS media, extracts were prepared, and Western analysis was
performed using CBS, Hsp26, and a-tubulin anti-bodies. The
CBS enzyme activity present in each extract is shown at the
bottom (n=3; standard deviation shown). (B) Lysates from cells
expressing the indicated human CBS allele were prepared and
subject to immunoprecipitation using Hsp26 directed anti-body.
Immunocomplexes were then analyzed by Western blot with CBS
anti-bodies. Lane labeled control is extract without IP.
Found at: doi:10.1371/journal.pgen.1000807.s003 (0.19 MB PDF)
Figure S4 CBSproteinlevels inall mutantsgrowninthepresence
or absence of bortezomib. The indicated mutants were expressed in
a cys4D strain (Wy35) grown in SC+CYS media in the presence or
absence of 50 mM bortezomib. After 24 hours, extracts were
prepared and Western analysis was performed using CBS antibody.
Found at: doi:10.1371/journal.pgen.1000807.s004 (0.70 MB PDF)
Figure S5 Effect of ssa2D and hsp104D on ethanol rescue of
mutant p53. (A) SSA2 or ssa2D yeast cells expressing the indicated
p53 alleles were grown in either in the presence or absence of
ethanol and assessed for growth in SC-ade-ura media after
24 hours by measuring OD600. (B) HSP104 or hsp104D yeast cells
expressing the indicated p53 alleles were grown in either in the
presence or absence of ethanol and assessed for growth in SC-ade-
ura media after 24 hours by measuring OD600.
Found at: doi:10.1371/journal.pgen.1000807.s005 (0.16 MB PDF)
Figure S6 Rescue of multiple mutant p53 by ethanol or
bortezomib treatment. Stationary phase culture of yeast yIG397
expressing the indicated human p53 allele was diluted 1:1000 in
SC–ade -ura media supplemented with either 4% ethanol or
50 mM bortezomib and grown at 30uC for 24 h. Growth was then
determined by measuring OD at 600 nm.
Found at: doi:10.1371/journal.pgen.1000807.s006 (0.07 MB PDF)
Figure S7 CBS protein and activity in human cells treated with
bortezomib. (A) Primary fibroblast cells expressing the indicated
CBS allele were grown to 80% confluency at which time
Bortezomib (18 mM) was added. After seven hours protein was
harvested and Hsp70, CBS, and actin protein levels were measured
by immunoblot. (B) Comparison of Hsp70 induction in bortezomib
vs. MG132 cells. Gels were scanned using imaging software (Alpha
Innotech 2.0) and the average induction is shown. Error bars show
standard deviation. P,2.0610
25 (t-test, two-sided).
Found at: doi:10.1371/journal.pgen.1000807.s007 (0.64 MB PDF)
Figure S8 Serum total homocysteine and methionine levels in
Tg-I278T Cbs2/2 animals treated with bortezomib. Error bars
show standard deviation *P,0.05 (t-test, 2-sided).
Found at: doi:10.1371/journal.pgen.1000807.s008 (0.05 MB PDF)
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